Safety and immunogenicity of a first dose of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic stem-cells recipients.

Abstract

This was a monocentric prospective study testing the efficacy and safety of a first injection of BNT162b2 (Pfizer-BioNTech) in 112 Allo-HSCT patients. Antibody response to SARS-CoV-2 spike protein receptor-binding domain was tested at the time of the second injection (Roche Elecsys). The study also included a non-randomized control arm of 26 healthy controls. This study shows that a first dose of SARS-CoV-2 messenger RNA vaccine is safe and provides a 55% rate of seroconversion in allotransplanted patients compared to 100% for the controls (p < 0.001). Factors influencing the absence of response in patients were recent transplantation (<2 years), lymphopenia (<1 × 109/L) and immunosuppressive treatment or chemotherapy at the time of vaccination.

• Authors: Patrice Chevallier, Marianne Coste-Burel, Amandine Le Bourgeois, Pierre Peterlin, Alice Garnier, Marie C Béné, Berthe-Marie Imbert, Thomas Drumel, Steven Le Gouill, Philippe Moreau, Beatrice Mahe, Viviane Dubruille, Nicolas Blin, Anne Lok, Cyrille Touzeau, Thomas Gastinne, Maxime Jullien, Sophie Vanthygem, Thierry Guillaume
• Journal: EJHaem (EJHaem) Vol. 2 Issue 3 Pg. 520-524 (Aug 2021) ISSN: 2688-6146 [Electronic] United States
• PMID: 34226903 (Publication Type: Journal Article)
• Copyright: © 2021 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.